Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis.
cancer immunotherapy
drug induced pneumonitis
immune-related adverse event (irae)
infliximab
non-small cell lung carcinoma (nsclc)
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
accepted:
10
02
2022
entrez:
30
3
2022
pubmed:
31
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) are important novel agents used in advanced non-small cell lung cancer (NSCLC) standard regimens; however, their use increases the risk of immune-related adverse effects (IRAEs). The incidence of IRAE pneumonitis is well documented in ICI use. Corticosteroids continue to be the mainstay of treatment for IRAEs. Here we report one of the first cases of using infliximab to treat durvalumab-associated pneumonitis.
Identifiants
pubmed: 35350507
doi: 10.7759/cureus.22295
pmc: PMC8933124
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e22295Informations de copyright
Copyright © 2022, Huang et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Thorac Cancer. 2020 May;11(5):1280-1287
pubmed: 32160383
Clin Transl Radiat Oncol. 2020 May 30;23:85-88
pubmed: 32529055
Nat Rev Immunol. 2020 Feb;20(2):75-76
pubmed: 31925406
Mol Clin Oncol. 2021 Oct;15(4):221
pubmed: 34476105
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
J Thorac Oncol. 2021 Oct;16(10):1759-1764
pubmed: 34265432
Genome Med. 2019 Jun 20;11(1):39
pubmed: 31221204
Cancer Med. 2018 Aug;7(8):4115-4120
pubmed: 29797416
Oncologist. 2021 May;26(5):433-438
pubmed: 33687763
Chest. 2017 Aug;152(2):271-281
pubmed: 28499515
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Drug Discov Ther. 2019 Jul 22;13(3):164-167
pubmed: 31257354
Lancet Oncol. 2018 Apr;19(4):521-536
pubmed: 29545095
Expert Rev Anticancer Ther. 2019 Dec;19(12):1009-1016
pubmed: 31782989
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33414264
Cancer Med. 2020 Jul;9(13):4622-4631
pubmed: 32372571
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Intern Med. 2020 Dec 1;59(23):3055-3059
pubmed: 32727989